Meropenem Wh

Meropenem, the active ingredient in Meropenem Wh, is a carbapenem antibiotic presented as a powder for solution for injection for intravenous use. It treats serious bacterial infections such as complicated intra‑abdominal infections, urinary tract infections, hospital‑acquired pneumonia, skin and soft‑tissue infections, and septicemia in hospitalized patients.

GNH USA supplies Meropenem Wh as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance and timely delivery.

Meropenem is a broad‑spectrum carbapenem antibiotic used to treat severe bacterial infections across several organ systems.

- Complicated intra‑abdominal infections: provides bactericidal activity against mixed aerobic and anaerobic pathogens, helping resolve infection. - Complicated urinary tract infections: eradicates resistant Gram‑negative and Gram‑positive organisms, achieving clinical cure. - Hospital‑acquired pneumonia: targets multidrug‑resistant bacteria in the lungs, improving respiratory outcomes. - Skin and soft‑tissue infections: eliminates susceptible pathogens, facilitating healing. - Septicemia: rapidly reduces bloodstream bacterial load, supporting recovery.

Adverse reactions to Meropenem may vary in frequency and severity.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: loose stools, may be associated with C. difficile. - Injection site pain: local discomfort during infusion.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring emergency care. - Seizures: risk increased in renal impairment or CNS disease. - Clostridioides difficile colitis: potentially severe intestinal infection.

When using Meropenem, clinicians should consider several safety measures.

- Renal function: adjust dose in patients with impaired kidney function. - Hypersensitivity: avoid in individuals with known carbapenem or β‑lactam allergy. - CNS disorders: monitor for seizures, especially in patients with a history of epilepsy. - Pregnancy and lactation: use only if potential benefit justifies risk, as safety data are limited. - Concomitant valproic acid: monitor for decreased serum levels of valproate. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Valproic acid: may reduce valproate concentrations, risking seizure breakthrough. - Probenecid: can increase meropenem plasma levels, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Aminoglycosides: additive nephrotoxicity; monitor renal function. - Loop diuretics: may enhance nephrotoxic potential. - Anticoagulants (warfarin): possible alteration of INR; check coagulation parameters. - Other β‑lactams: potential for competitive inhibition; assess clinical response.